ライフサイエンスコーパス: visual analogue scale

1 pnea and chest tightness were evaluated on a visual analogue scale.

2 ith activity) greater than 13 mm on a 100-mm visual analogue scale.

3 placebo for most FACT-P endpoints and EQ-5D visual analogue scale.

4 d urge) for alcohol, assessed by the Alcohol Visual Analogue Scale.

5 ily symptoms were rated using a 0- to 100-mm visual analogue scale.

6 Quality of life was assessed by visual analogue scale.

7 tion with life scale and the quality of life visual analogue scale.

8 ry outcome was pain, which was assessed by a visual analogue scale.

9 pleasantness (hedonic response) on a 100-mm visual analogue scale.

10 pain 1 week after treatment, according to a visual analogue scale.

11 rated the magnitude of the evoked pain on a visual analogue scale.

12 atients recorded hypoglycaemia symptoms on a visual analogue scale.

13 ts at home on a weekly basis using validated visual analogue scales.

14 Symptoms were evaluated by visual analogue scales.

15 l, 300 kcal) and postprandial symptoms using visual analogue scales.

16 fullness, and hunger were assessed by using visual analogue scales.

17 Rating Scale, Young Mania Rating Scale, and visual analogue scales.

18 surveillance procedures and the device with visual analogue scales.

19 ay of surgery (difference in mean score on a visual-analogue scale, 10.2 mm; 95 percent confidence in

20 x (224 [28%] of 812 vs 99 [16%] of 623), and visual analogue scale (218 [27%] of 803 vs 106 of [18%]

21 on; postprandial symptoms were measured with visual analogue scales 30 minutes after a meal.

22 pain (mean difference (MD) on 100-millimeter visual analogue scale = -7.7 mm; 95% CI -13.92 to -1.43;

23 Subjective data were collected according to visual analogue scales after 8 weeks of denture-wearing.

24 At 12 months, the visual analogue scale and the other Seattle Angina Quest

25 Individuals graded heel pain with a visual analogue scale and underwent B-mode ultrasonograp

26 tudy showed that quality-of-life data (EQ-5D visual analogue scale and WPA-IS Question 9) are similar

27 The patient reported pain of 8-10 in VAS (Visual Analogue Scale) and had an ODI (Oswestry Disabili

28 ject recorded pain intensity (using a 100-mm visual-analogue scale) and intake of oral analgesia in a

29 The body ache improved by 100% on the visual analogue scale, and the electromyographic dischar

30 atching of symptom intensity to line length (visual analogue scales), are reviewed for their reliabil

31 improvement were change from baseline in the visual analogue scale area under the curve (VAS AUC) to

32 They completed visual analogue scales assessing the severity of 5 gastr

33 Measures of appetite were obtained by using visual analogue scales before and after meals.

34 The Cytosponge was rated favorably, using a visual analogue scale, compared with endoscopy (p < 0.00

35 ain as assessed by analgesic consumption and visual analogue scales, complications, and length of hos

36 ode Island Change Assessment; and 2) sums of visual analogue scale craving ratings administered durin

37 onth and one-year follow-up, and the EuroQOL Visual Analogue Scale (EQ-VAS) and EuroQOL 5-Dimensional

38 ety were measured before and after cues with visual analogue scales for desire to use cocaine now and

39 ife, as measured by the EuroQol 5 Dimensions visual analogue scale, improved by 7.2 points (SD 21.3)

40 change from baseline to week 15 on the EQ-5D visual analogue scale, in contrast to a clinically meani

41 The participants also completed a visual analogue scale instrument on level of discomfort

42 nolence (via Karolinska Sleepiness Scale and Visual Analogue Scale measures) and sleep (via polysomno

43 de also significantly improved scores on the visual analogue scale of cough (mean difference vs. plac

44 Secondary end points were visual analogue scale of cough and the St. George's Resp

45 aggressive/destructive behavior subscale; a visual analogue scale of the most troublesome symptom; a

46 e Seattle Angina Questionnaire and a generic visual analogue scale on health status.

47 area under the curve (AUC) of the score on a visual-analogue scale over the course of 72 hours, and t

48 ad better peak-season rhinitis scores on the visual-analogue scale (P=0.006), peak-season daily nasal

49 ting Scale (r = -0.4965, P < 0.01), Rhinitis Visual Analogue Scale (r = 0.5722, P < 0.01) and asthma

50 e was subjective pain as measured by a 10-cm visual analogue scale ranging from 0 (no pain) to 10 (wo

51 bjective snoring severity (SS, measured on a visual analogue scale ranging from 0 to 10) and the obje

52 rted dyspnea (treatment difference, 0.7 on a visual-analogue scale ranging from 1 to 10; 95% confiden

53 Rhinitis severity was assessed using a visual analogue scale; rhinitis was classified according

54 ), a statistically significant difference in visual analogue scale score in favor of acupuncture (6.3

55 Outcome measures included pain (visual analogue scale score), functional assessment (Con

56 The mean nausea score on the Visual Analogue Scale (score 0-10) was greater during th

57 EuroQol-visual analogue scale scores were lower for frail compar

58 h, and 24 h vs 14 of 61 [23%]; p=0.044) and visual analogue scale through day 14 (8214 mm x h [SD 87

59 Isowork dyspnea decreased as assessed with a visual analogue scale (VAS) (79.6 +/- 5.2 versus 49.3 +/

60 iate neuropathic pain relief was assessed by visual analogue scale (VAS) after connecting the electro

61 Nasal visual analogue scale (VAS) and blockage scores were wor

62 Symptoms were assessed by a visual analogue scale (VAS) and symptom specific quality

63 Main outcome measures were visual analogue scale (VAS) assessments for "pain," "num

64 nificantly improved median score on a 100 mm visual analogue scale (VAS) by 5 mm (range -2 to 14; p=0

65 re assessed with the Tsui torticollis scale, Visual Analogue Scale (VAS) for pain and Fugl-Meyer scal

66 days and breathlessness measured on a 100 mm visual analogue scale (VAS) in the 2 h after initiation

67 Visual Analogue Scale (VAS) is a validated tool to asses

68 Cancer (EORTC) symptom scale, global health visual analogue scale (VAS) of EQ-5D, and liver volume.

69 Weekly visual analogue scale (VAS) scores for myalgia and speci

70 ol items according to EPOS control criteria, visual analogue scale (VAS) scores for total and individ

71 rs") comprising the UCEIS were scored with a visual analogue scale (VAS) to assess overall severity.

72 Validated questionnaires and a visual analogue scale (VAS) were used for the assessment

73 ubjects (total n=28) rated pleasantness on a visual analogue scale (VAS) when we stroked with a soft

74 naire (DEQ-5), rating of eye dryness using a visual analogue scale (VAS), and noninvasive tear film b

75 ensitivity C-reactive protein (hs-CRP) and a visual analogue scale (VAS), respectively.

76 ctivity of uncontrolled rhinitis assessed by visual analogue scale (VAS).

77 those seen with the wild-type Elstar using a visual analogue scale (VAS).

78 as evaluated by both ARIA severity items and visual analogue scale (VAS).

79 was assessed with EuroQol questionnaire and visual analogue scale (VAS).

80 Discomfort scores were also assessed with a visual analogue scale (VAS).

81 before and after PV was measured by using a visual analogue scale (VAS).

82 ectional study) and (iii) to follow-up using visual analogue scale (VAS).

83 y scored the pain intensity on an electronic visual analogue scale (VAS).

84 the EHP30 Quality-of-Life Questionnaire and visual analogue scales (VAS) for dysmenorrhea, chronic p

85 ire (HAQ), Short Form Health Survey (SF-36), Visual Analogue Scales (VAS) for gastrointestinal compla

86 nd Apple App Store) collects data from daily visual analogue scales (VAS) for overall allergic sympto

87 as determined by reported symptoms and using visual analogue scales (VAS) for pain, tingling and disc

88 arison measures, participants completed four Visual Analogue Scales (VAS) to assess musical sound qua

89 and medication score (SMS) assessed by daily visual analogue scales (VAS).

90 bility to communicate pain (measured using a visual analogue scale [VAS]) and length of ICU stay.

91 scale), eye dryness score (EDS) >/=40 (0-100 visual analogue scale [VAS]), and history of artificial

92 A Visual Analogue Scale was used to provide a quantitative

93 te (M) and whole-body thermal sensation on a visual analogue scale (WBTS) ranging from 0 mm (very col

94 Visual analogue scales were used to assess hunger weekly

95 Visual analogue scales were used to assess indexes of sa

96 Visual analogue scales were used to assess subjects' hun

97 eing (a mean decrease of 1.38 mm on a 100-mm visual-analogue scale), whereas the natalizumab groups r

98 articipation), pain (assessed on an 11-point visual-analogue scale, with higher scores indicating mor

99 pain from these ulcers (measured on a 100-mm visual-analogue scale, with higher scores indicating wor